Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Int J Clin Pract
; 69(12): 1496-507, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-26299520
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Hyperplasia
/
Vasodilator Agents
/
Cardiovascular Diseases
/
Phosphodiesterase 5 Inhibitors
/
Lower Urinary Tract Symptoms
/
Tadalafil
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Int J Clin Pract
Journal subject:
MEDICINA
Year:
2015
Document type:
Article
Affiliation country:
Country of publication: